History of NTD
NTD Eurofins – A History of Innovation
Since its inception, NTD Eurofins has demonstrated a history of innovation, beginning with its work in neural tube defect research and continuing to where it stands today, at the forefront of prenatal care and genetic screening.
NTD Eurofins was the first to introduce;
- ONTD Screening
- Down Syndrome Screening
- First Trimester Screening
- Early Onset Preeclampsia Screening
Today, NTD Eurofins provides first and second trimester prenatal screening, genetic carrier screening, and hereditary cancer screening services to universities, medical centers, hospitals, laboratories, obstetricians and maternal fetal medicine (MFM) specialists worldwide through an accredited facility owned and operated by Eurofins Scientific. With an unwavering commitment to quality, combined with industry-leading best practices, NTD Eurofins remains at the forefront of research and innovation in maternal fetal healthcare industry.
Over Three Decades of Prenatal Screening
NTD Timeline
1976
AFP
First AFP screening for neural tube defects introduced in the United States of America by James N. Macri.
1983
NTD Labs Founded
NTD Labs was incorporated by Dr. Macri as a prenatal screening and research laboratory.
1989
Free Beta hCG
Discovered free beta hCG as the most discriminatory biochemical marker for Down syndrome.
1995
First Trimester Screen | Fß
NTD introduces first trimester Down syndrome screening.
2003
Landmark NICHD Study
Large multi-center study published in the New England Journal of Medicine validates the advantages of the free Beta hCG/PAPP-A/NT protocol.
2005
Nasal Bone Assessment
Fetal nasal bone assessment protocol introduced as part of NTD Labs first trimester Down syndrome screening protocol.
2007
Instant Risk Assessment
NTD introduces web portal to facilitate Instant Risk Assessment reporting within the Down syndrome screening protocol.
2013
Early Onset Preeclampsia Screen
NTD introduces the first serum screening test for early onset preeclampsia in the U.S.
2013
NIPT
NTD offers verifi cell free DNA screening through Illumina, Inc.
2015
AFP in First Trimester
NTD enhances it’s screening protocol with the addition of alpha fetoprotein (AFP) in the first trimester to improve the detection rate of Down syndrome. Learn more.
2016
Eurofins NTD Acquisition
NTD is acquired by Eurofins Scientific. Learn more.
2017
Maternal Fetal ScreenSM | T1
NTD launches Maternal Fetal ScreenSM | T1, offering both T21, 18/13 and early onset preeclampsia risk assessment results on one patient report. Learn more.
2018
NTD Offers Genetic Testing
NTD joins with sister laboratory, EGL Genetics, to offer genetic carrier and hereditary cancer screening services.